```html

Amiodarone‑Induced Thyroid Dysfunction

Overview

Amiodarone‑induced thyroid dysfunction (AITD) refers to abnormal thyroid hormone production that occurs as a side‑effect of the anti‑arrhythmic drug amiodarone. Because amiodarone contains about 37% iodine by weight, it can profoundly affect thyroid physiology, leading to either hypothyroidism (underactive thyroid) or hyperthyroidism (overactive thyroid).

Who it affects: Adults of any age taking amiodarone, most commonly patients with atrial fibrillation, ventricular tachycardia, or ventricular fibrillation. Women are slightly more prone to hypothyroidism, whereas men have a higher incidence of hyperthyroidism, though the differences are modest.

Prevalence: Studies from the United States, Europe, and Asia report that 10‑20% of patients develop hypothyroidism and 5‑10% develop hyperthyroidism while on amiodarone therapy. The risk rises with longer treatment duration (>6 months) and higher cumulative doses.<sup>1,2</sup>

Symptoms

Because thyroid hormones influence virtually every organ system, the symptom spectrum is broad. Symptoms may differ between amiodarone‑induced hypothyroidism (AIH) and amiodarone‑induced hyperthyroidism (AIH‑HT).

Amiodarone‑Induced Hypothyroidism (AIH)

• Fatigue & weakness: Persistent tiredness that does not improve with rest.
• Weight gain: Often modest (5‑10 lb) despite unchanged diet.
• Cold intolerance: Feeling unusually cold, especially in hands and feet.
• Dry skin and hair loss: Rough, flaky skin; thinning hair on scalp and eyebrows.
• Constipation: Infrequent, hard stools.
• Depression or low mood: Mood changes, difficulty concentrating.
• Bradycardia: Slow heart rate (<60 bpm) which can compound underlying arrhythmias.
• Elevated cholesterol: Often detected on routine labs.

Amiodarone‑Induced Hyperthyroidism (AIH‑HT)

• Heat intolerance & sweating: Feeling hot, excessive perspiration.
• Weight loss: Unexplained loss despite stable or increased appetite.
• Tremor: Fine shaking of hands.
• Palpitations & tachycardia: Rapid heart rate (>100 bpm) that may worsen existing arrhythmias.
• Anxiety or nervousness: Heightened irritability, difficulty sleeping.
• Diarrhea: More frequent, loose stools.
• Heat‑sensitive skin: Flushed face, warm skin.
• Eye changes (Graves‑like): Lid retraction, eye irritation (rare).

Because amiodarone itself can cause pulmonary, hepatic, and dermatologic side‑effects, any new symptoms in a patient receiving the drug should prompt a clinical review.

Causes and Risk Factors

Pathophysiology

Amiodarone disrupts thyroid function through several mechanisms:

1. Iodine overload: A single 200 mg tablet delivers ~75 mg of iodine—far exceeding the daily recommended 150 µg. Excess iodine initially triggers the Wolff–Chaikoff effect (temporary inhibition of hormone synthesis). In some individuals, the gland “escapes” this block, leading to hyperthyroidism (type 1). Others fail to escape, resulting in sustained hypothyroidism (type 2).
2. Direct cytotoxicity: The drug and its metabolites (esp. desethylamiodarone) accumulate in thyroid follicular cells, causing inflammation and destructive thyroiditis.
3. Altered peripheral conversion: Amiodarone inhibits 5′‑deiodinase, reducing conversion of T4 to the active T3, which can mask hyperthyroidism or exacerbate hypothyroidism.

Risk Factors

• Pre‑existing thyroid disease: Subclinical hypothyroidism or autoimmune thyroiditis increase risk of AIH.
• Geographic iodine status: Residents of iodine‑deficient regions are more prone to hyperthyroidism, whereas iodine‑replete populations have higher hypothyroidism rates.
• High cumulative dose: > 400 g total amiodarone (≈2 years of 200 mg daily) markedly raises risk.
• Age > 60 years: Older adults have reduced thyroid reserve.
• Sex: Female sex slightly raises AIH risk; male sex is linked with AIH‑HT.
• Concomitant drugs: Lithium, interferon‑α, or other iodine‑containing contrast agents can synergize.

Diagnosis

Accurate diagnosis requires a combination of clinical assessment, laboratory tests, and imaging.

Laboratory Evaluation

• Serum Thyroid‑Stimulating Hormone (TSH): Primary screening. Elevated TSH → hypothyroidism; suppressed (<0.1 mIU/L) → hyperthyroidism.
• Free Thyroxine (Free T4) & Free Triiodothyronine (Free T3): Distinguish subclinical from overt disease.
• Thyroid Antibodies (TPO‑Ab, Tg‑Ab, TRAb): Positive antibodies suggest autoimmune etiology (type 1 hyperthyroidism).
• Serum amiodarone level (optional): Helpful in research settings; not routine.

Imaging & Additional Tests

• Radioactive Iodine Uptake (RAIU) Scan: Low uptake (<5%) indicates type 2 (destructive) hyperthyroidism; high/normal uptake suggests type 1 (iodine‑induced). Hypothyroid patients usually show low uptake.
• Thyroid Ultrasound: Detects nodules, inflammation, or atrophy.
• Echocardiography & ECG: Baseline cardiac evaluation before any change in amiodarone dosing.

Guidelines from the American Thyroid Association (ATA) recommend checking TSH, Free T4, and T3 within 4‑6 weeks after initiating amiodarone, then every 3‑6 months thereafter.<sup>3</sup>

Treatment Options

Treatment is individualized based on the type of dysfunction, severity, and cardiac status.

Amiodarone‑Induced Hypothyroidism (AIH)

1. Levothyroxine replacement: Start with 25‑50 µg daily, titrating to keep TSH within the target range (0.5‑2.5 mIU/L for most patients). Dose adjustments are often needed because amiodarone prolongs the half‑life of levothyroxine.
2. Continue amiodarone if cardiac benefit outweighs risk: In many cases, thyroid hormone replacement allows continuation of amiodarone.
3. Alternative anti‑arrhythmic: If hypothyroidism is severe, refractory, or patient cannot tolerate levothyroxine, discuss switching to another agent (e.g., dronedarone, sotalol) with a cardiologist.

Amiodarone‑Induced Hyperthyroidism (AIH‑HT)

AIH‑HT is classified into two types, each requiring a different approach.

• Type 1 (iodine‑induced, often in patients with underlying nodular disease):
  • First‑line: Thionamides (methimazole 15‑30 mg/day or propylthiouracil 100‑200 mg q6‑8 h). Aim for euthyroidism within 4‑6 weeks.
  • Adjunct: Potassium iodide (e.g., saturated solution of potassium iodide – 5 drops three times daily) after 2‑3 weeks of thionamide to inhibit hormone release (the “Wolff‑Chaikoff” square‑wave).
  • Beta‑blockers (propranolol 20‑40 mg q6 h) for symptom control.
• Type 2 (destructive thyroiditis):
  • Glucocorticoids: Prednisone 40‑60 mg daily for 1–2 weeks, then taper over 4‑6 weeks. Reduces inflammatory hormone release.
  • If inadequate response, combine low‑dose thionamide with steroids.

When hyperthyroidism is severe or refractory, consider:

• Radioactive iodine therapy (RAI): Often avoided while on amiodarone because the large iodine pool reduces uptake; may be used after drug discontinuation.
• Thyroidectomy: Definitive treatment for life‑threatening thyrotoxicosis, especially when rapid control is needed and steroids are contraindicated.
• Discontinuation of amiodarone: Not always feasible due to arrhythmia control; when possible, switch to another anti‑arrhythmic as decided by cardiology.

Lifestyle & Supportive Measures

• Maintain a balanced diet; avoid excess iodine (seaweed, iodinated contrast, certain supplements).
• Stay hydrated and monitor weight changes.
• Adhere to medication timing—levothyroxine best taken on an empty stomach, 30‑60 min before food.
• Regular follow‑up labs every 1‑3 months during treatment adjustments.

Living with Amiodarone‑Induced Thyroid Dysfunction

Daily Management Tips

• Medication calendar: Use a pill organizer or smartphone reminder for levothyroxine, thionamides, or steroids.
• Symptom diary: Record heart rate, temperature sensitivity, weight, and mood; bring this to each appointment.
• Coordinate care: Keep both cardiology and endocrinology teams informed of lab results and medication changes.
• Nutrition: Limit high‑iodine foods (kelp, iodine‑rich salts). Aim for 150‑200 µg of iodine per day from regular diet.
• Exercise: Moderate activity (e.g., walking, stationary cycling) improves cardiovascular health without over‑stressing the thyroid.
• Pregnancy considerations: Women of childbearing potential should discuss thyroid management early; both hypothyroidism and hyperthyroidism affect fetal development.

Monitoring Schedule

Test	Frequency
TSH, Free T4, Free T3	Baseline, 6 weeks, then every 3‑6 months
Thyroid antibodies (if initial abnormal)	Once; repeat if clinical change
Cardiac ECG	Every 6‑12 months or after dose changes

Prevention

• Baseline thyroid screening: Obtain TSH, Free T4, and antibodies before starting amiodarone.
• Risk‑adapted dosing: Use the lowest effective dose (commonly 200 mg daily) and avoid loading doses when possible.
• Regular monitoring: Early detection (within the first 6 months) prevents progression to overt disease.
• Patient education: Inform patients about iodine‑rich foods and the importance of reporting new symptoms.
• Consider alternative agents: For patients with known thyroid autoimmunity, discuss alternatives with the cardiology team.

Complications

If left untreated, AITD can lead to serious sequelae:

• Cardiovascular:
  • Hypothyroidism → bradyarrhythmias, worsening heart failure.
  • Hyperthyroidism → atrial fibrillation, ventricular tachyarrhythmias, high-output heart failure.
• Metabolic: Dyslipidemia, weight changes, insulin resistance.
• Neurologic: Cognitive impairment, depression, anxiety.
• Bone health: Long‑standing hyperthyroidism accelerates bone loss and increases fracture risk.
• Pregnancy: Untreated maternal hyperthyroidism raises risk of pre‑eclampsia, preterm birth, and fetal tachycardia.

When to Seek Emergency Care

---

Sources:
1. Mayo Clinic. “Amiodarone (Oral Route).” Accessed 2024.
2. Dosiou C., et al. “Thyroid dysfunction induced by amiodarone: epidemiology and clinical management.” Endocrine Reviews, 2022.
3. American Thyroid Association. “Guidelines for the Treatment of Thyroid Disease During Pregnancy.” 2023.
4. CDC. “Iodine Deficiency.” 2024.
5. Cleveland Clinic. “Amiodarone and the Thyroid.” 2023.

```